South Africa's competition watchdog is investigating drugmakers Novo Nordisk and Sanofi over possible anti-competitive ...

AbbVie will pay up to $2.2 billion to develop Danish drugmaker Gubra's obesity drug. AI takes center stage at HIMSS ...

Today's Research Daily features new research reports on 16 major stocks, including Novo Nordisk A/S (NVO), The Coca-Cola ...

Over 90 nutritionists have hit back at Ozempic maker Novo Nordisk's project to update the Nova classification for ...

Novo Nordisk A/S and Sanofi are facing an investigation in South Africa over concerns about potential anti-competitive practices in the human insulin pen market.

Stifel Nicolaus cut shares of Novo Nordisk A/S (NYSE:NVO – Free Report) from a buy rating to a hold rating in a report issued ...

Novo Nordisk and Sanofi are facing an investigation in South Africa over concerns about potential anti-competitive practices ...

Pfizer's Q4/24 results showed significant improvements, with total revenue up 21.9% YoY and adjusted diluted EPS increasing ...

Online pharmacies and private providers have been urged to “act responsibly” and ensure that the drugs are only prescribed to ...

AbbVie's strategic move into the obesity market through a partnership with Gubra A/S shows potential but won't impact revenue ...

California made a bold announcement that it would manufacture a state-branded, low-cost insulin. It still is not here.

CAPE TOWN - As the globe observes World Obesity Day. South Africa has come out as the African country with the highest number ...